Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) Stock Ticker

NASDAQ: ARTV · Healthcare · Biotechnology
$6.99-6.68%
USD · as of 2026-09-28 · market cap $341.7M
Open ARTV in TickrDownload for iPhone

ARTV right now

Down 37% in the last month.
Options expect by Oct 6±11.4%
Options expect by Oct 29±23.7%
Priced in for Nov 11 earnings±28.3%
IV rank (30-day)38% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full ARTV picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on ARTV
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

ARTV stock facts

Ticker symbolARTV
ExchangeNASDAQ Global Market
SectorHealthcare
IndustryBiotechnology
Market cap$341.7M
CEOFred Aslan
Employees115
HeadquartersSan Diego, CA, US
IPO date2024-07-19
Websitewww.artivabio.com

What you can see for ARTV on Tickr

Live ARTV price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ARTV report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Artiva Biotherapeutics, Inc.?

The ticker symbol for Artiva Biotherapeutics, Inc. is ARTV, listed on the NASDAQ Global Market.

What is ARTV?

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of…

HomeExploreMarketLists
All pages